Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration.
about
Clinical review: immunodepression in the surgical patient and increased susceptibility to infectionSerum biomarkers in acute respiratory distress syndrome an ailing prognosticatorBloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.Modulation of paired immunoglobulin-like type 2 receptor signaling alters the host response to Staphylococcus aureus-induced pneumoniaSoluble ST2 plasma concentrations predict mortality in severe sepsis.Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitroDysregulation of in vitro cytokine production by monocytes during sepsisTumor necrosis factor alpha has a protective role in a murine model of systemic candidiasisSerum-induced potentiation of tumor necrosis factor alpha production by human monocytes in response to staphylococcal peptidoglycan: involvement of different serum factorsEffect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfectionProtein kinase C modulates pulmonary endothelial permeability: a paradigm for acute lung injury.Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion.Roles of the bacterial cell wall and capsule in induction of tumor necrosis factor alpha by type III group B streptococci.Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls.A protective role of platelet-activating factor in murine candidiasis.Effects of granulocyte and granulocyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis.Cytokines and the response to infection.Different role of cytokine mediators in septic shock related to meningococcal disease and surgery/polytrauma.The tissue distribution of tumor necrosis factor biosynthesis during endotoxemiaBench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department.Biomarkers in acute lung injury.Cytokines. 2. Cytokines and lung inflammation: mechanisms of neutrophil recruitment to the lungImmunological perspectives in prevention and treatment of nosocomial pneumonia.Cytokine gene regulation by PGE(2), LTB(4) and PAFGenetic epidemiology of acute respiratory distress syndrome: implications for future prevention and treatmentCytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock.Optimization of cell-based assays to quantify the anti-inflammatory/allergic potential of test substances in 96-well format.Choice of bacteria in animal models of sepsis.The pathogenesis of ventilator-associated pneumonia: II. The lower respiratory tract.Alcohol, tumor necrosis factor, and tuberculosis.Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections.Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia.Monitoring of immunotherapy with cytokines or monoclonal antibodies.Cytokines, sepsis and immunomodulation.Is sepsis a mediator-inhibitor mismatch?Tumor necrosis factor and endotoxin do not directly affect in vitro diaphragm function.Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.A novel alveolar type I cell-specific biochemical marker of human acute lung injury.The American-European Consensus Conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome.LPS-induced serum TNF production and lethality in mice: effect of L-carnitine and some acyl-derivatives.
P2860
Q24796900-DDBF93FF-926B-4341-AD11-4D3E1B2616EAQ24815239-6EC3CE4E-4AE0-4C07-A414-934A0D45D322Q33535029-EF7AA11D-DB95-49E2-BABB-BE339FB95B59Q33675732-820FE2C4-5C74-4C8B-9147-C00107FB6086Q33722112-00E688C8-E287-43BC-AE19-FC33E7D53A86Q34125796-D1900F4B-AB11-4FCF-A66C-B68231D2BD49Q34211246-4278C4FB-F92A-49F1-A06A-3727ED0FE2F6Q34529190-38A30145-1AD1-465E-BE37-4E9613F0A4D9Q34537002-521D70EA-3715-416A-A8C1-D814C726084AQ34616215-48486884-AC1A-4972-BDD5-132390FFE427Q35062604-E3F9D5B3-C66A-468A-8836-4D86E8398032Q35473213-97CC443D-3250-473E-A264-4C9A7FDA2DD2Q35531363-49D13FF2-A37F-455B-AF72-E4E362DA1159Q35533388-E2DE75C9-A1F7-40CE-B762-7AB6A90C1F6EQ35545393-C35C90E3-32A9-4C4A-A17F-948EB5E1C8B2Q35553643-9DFA3A74-6E55-4225-ABCE-B5D72B4498D6Q35658446-6C182257-C6F1-40D7-8849-054184A7C34EQ35732460-5325352C-E16A-4DDD-A1D5-26BECCE98A3BQ35820994-9BD72FCF-CC18-49F1-8C3E-97096B011348Q35853666-147E4717-0C6B-4179-9129-DE5F080BA46DQ35958312-644EBFA5-BF7F-4AF0-8214-496D00285342Q36284578-E24566D9-6785-4B33-94E5-C20A0BBAC388Q36363725-2FDFE093-E6DE-45CA-85F0-C072ED0BE1CDQ36626924-D4BC421C-7748-4CE7-8D01-4ACC892A3375Q36645151-B71777F7-C01A-4F76-9928-C2D0A3A9DF3FQ36928868-67D40A59-C0BE-45F6-865B-E44B0B9C2D7BQ39633209-7808C407-F594-41AA-A1B1-4BCD5C8D1AE4Q40267706-1B57CC25-62E9-4A1E-A6BB-F84CE738BC75Q40476978-5103A9DE-E6BE-45DB-A758-A9487E6AC683Q40539747-B08CDE84-85E4-4FDE-A756-6D44434A9FF3Q40569186-C0D26063-6B31-4B1C-A7F3-57A787F10A14Q40677427-87514286-1698-4DCF-984D-3F2710EF740EQ40689787-3570D9CA-151E-40C9-8339-78EEBA58105BQ40896076-8C1DCF99-1C17-49F6-9EC6-F7BA4E5AB26CQ40990069-A67D8395-2A24-466D-98E4-4A965E84FC68Q41536829-2920FAE0-C2DC-4BB9-A2D9-1763C7EC5147Q41661156-AEBAB762-BF5E-4C9E-B3AD-6550C4F119DDQ41724321-DD935AA5-00D3-4EF2-95AE-191C4E06D026Q41752313-B104207C-17E6-4114-B718-32058D5E554BQ41852727-220DD146-82A6-40BC-ABDF-D8A4BB09C862
P2860
Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Plasma tumor necrosis factor i ...... ylprednisolone administration.
@en
Plasma tumor necrosis factor i ...... ylprednisolone administration.
@nl
type
label
Plasma tumor necrosis factor i ...... ylprednisolone administration.
@en
Plasma tumor necrosis factor i ...... ylprednisolone administration.
@nl
prefLabel
Plasma tumor necrosis factor i ...... ylprednisolone administration.
@en
Plasma tumor necrosis factor i ...... ylprednisolone administration.
@nl
P2093
P2860
P356
P1476
Plasma tumor necrosis factor i ...... ylprednisolone administration.
@en
P2093
Montgomery AB
P2860
P356
10.1164/AJRCCM/141.1.94
P577
1990-01-01T00:00:00Z